BACKGROUND: Hepatic immune-related adverse events (irAE) including elevated liver function tests (transaminases) occur in 1.4-22.3% of melanoma patients receiving immune checkpoint inhibitors (ICPI) and constitute a potentially serious toxicity that is challenging to treat. In contrast to the liver transaminases alanine aminotransferase (ALT) and aspartate aminotransferase (AST), only little is known about the frequency and impact of gamma-glutamyl transferase (GGT) elevations. METHODS: GGT determined prior to and during therapy of metastatic melanoma patients treated with ICPI were retrospectively assessed in two independent cohorts (PD-1: n = 218, Ipi + Nivo: n = 148). Overall survival (OS) and best objective response were analyzed according to baseline and immune-related GGT (irGGT) elevations during treatment. RESULTS: In multivariate analysis, OS was reduced in patients with elevated baseline GGT (PD-1 group: hazard ratio [HR] 1.76, p = .0073; Ipi + Nivo group: HR 1.77, p = .032). Immune-related GGT elevation was recorded in 17% (PD-1 group) and 38.5% (Ipi + Nivo group). Of these patients, the majority (81 and 68%, respectively) had normal ALT and AST and showed no clinical signs of hepatotoxicity. Patients who experienced irGGT elevation had superior response (PD-1 group: odds ratio [OR] 3.57, p = .00072; Ipi + Nivo group: OR 1.74, p = .12) and OS (PD-1 group: HR 0.37, p = .0016; Ipi + Nivo group: HR 0.33, p = .00050). CONCLUSIONS: The frequency of hepatic irAE is currently underestimated. The addition of the sensitive enzyme GGT to the laboratory panel before and during therapy with ICPI allows to detect two to three times more patients developing hepatic or hepatobiliary toxicity than known so far. Immune-related GGT elevations correlate with response and favorable survival. Precis for use in the Table of Contents The frequency of hepatotoxicity under immune checkpoint blockade is currently underestimated. We suggest the addition of gamma-glutamyl transferase to the laboratory panel in checkpoint inhibitor patients for the detection of hepatobiliary toxicity.
BACKGROUND:Hepatic immune-related adverse events (irAE) including elevated liver function tests (transaminases) occur in 1.4-22.3% of melanomapatients receiving immune checkpoint inhibitors (ICPI) and constitute a potentially serious toxicity that is challenging to treat. In contrast to the liver transaminases alanine aminotransferase (ALT) and aspartate aminotransferase (AST), only little is known about the frequency and impact of gamma-glutamyl transferase (GGT) elevations. METHODS:GGT determined prior to and during therapy of metastatic melanomapatients treated with ICPI were retrospectively assessed in two independent cohorts (PD-1: n = 218, Ipi + Nivo: n = 148). Overall survival (OS) and best objective response were analyzed according to baseline and immune-related GGT (irGGT) elevations during treatment. RESULTS: In multivariate analysis, OS was reduced in patients with elevated baseline GGT (PD-1 group: hazard ratio [HR] 1.76, p = .0073; Ipi + Nivo group: HR 1.77, p = .032). Immune-related GGT elevation was recorded in 17% (PD-1 group) and 38.5% (Ipi + Nivo group). Of these patients, the majority (81 and 68%, respectively) had normal ALT and AST and showed no clinical signs of hepatotoxicity. Patients who experienced irGGT elevation had superior response (PD-1 group: odds ratio [OR] 3.57, p = .00072; Ipi + Nivo group: OR 1.74, p = .12) and OS (PD-1 group: HR 0.37, p = .0016; Ipi + Nivo group: HR 0.33, p = .00050). CONCLUSIONS: The frequency of hepatic irAE is currently underestimated. The addition of the sensitive enzyme GGT to the laboratory panel before and during therapy with ICPI allows to detect two to three times more patients developing hepatic or hepatobiliary toxicity than known so far. Immune-related GGT elevations correlate with response and favorable survival. Precis for use in the Table of Contents The frequency of hepatotoxicity under immune checkpoint blockade is currently underestimated. We suggest the addition of gamma-glutamyl transferase to the laboratory panel in checkpoint inhibitor patients for the detection of hepatobiliary toxicity.
Authors: Jeffrey S Weber; F Stephen Hodi; Jedd D Wolchok; Suzanne L Topalian; Dirk Schadendorf; James Larkin; Mario Sznol; Georgina V Long; Hewei Li; Ian M Waxman; Joel Jiang; Caroline Robert Journal: J Clin Oncol Date: 2016-11-14 Impact factor: 44.544
Authors: Dirk Schadendorf; Jedd D Wolchok; F Stephen Hodi; Vanna Chiarion-Sileni; Rene Gonzalez; Piotr Rutkowski; Jean-Jacques Grob; C Lance Cowey; Christopher D Lao; Jason Chesney; Caroline Robert; Kenneth Grossmann; David McDermott; Dana Walker; Rafia Bhore; James Larkin; Michael A Postow Journal: J Clin Oncol Date: 2017-08-25 Impact factor: 44.544
Authors: Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi Journal: N Engl J Med Date: 2015-04-20 Impact factor: 91.245
Authors: Caroline Robert; Jacob Schachter; Georgina V Long; Ana Arance; Jean Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona McNeil; Michal Lotem; James Larkin; Paul Lorigan; Bart Neyns; Christian U Blank; Omid Hamid; Christine Mateus; Ronnie Shapira-Frommer; Michele Kosh; Honghong Zhou; Nageatte Ibrahim; Scot Ebbinghaus; Antoni Ribas Journal: N Engl J Med Date: 2015-04-19 Impact factor: 91.245
Authors: James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok Journal: N Engl J Med Date: 2015-05-31 Impact factor: 91.245
Authors: Martina Sanlorenzo; Igor Vujic; Adil Daud; Alain Algazi; Matthew Gubens; Sara Alcántara Luna; Kevin Lin; Pietro Quaglino; Klemens Rappersberger; Susana Ortiz-Urda Journal: JAMA Dermatol Date: 2015-11 Impact factor: 10.282
Authors: Fiamma Berner; David Bomze; Stefan Diem; Omar Hasan Ali; Mirjam Fässler; Sandra Ring; Rebekka Niederer; Christoph J Ackermann; Petra Baumgaertner; Natalia Pikor; Cristina Gil Cruz; Willem van de Veen; Mübeccel Akdis; Sergey Nikolaev; Heinz Läubli; Alfred Zippelius; Fabienne Hartmann; Hung-Wei Cheng; Gideon Hönger; Mike Recher; Jonathan Goldman; Antonio Cozzio; Martin Früh; Jacques Neefjes; Christoph Driessen; Burkhard Ludewig; Ahmed N Hegazy; Wolfram Jochum; Daniel E Speiser; Lukas Flatz Journal: JAMA Oncol Date: 2019-07-01 Impact factor: 31.777
Authors: Antoni Ribas; Igor Puzanov; Reinhard Dummer; Dirk Schadendorf; Omid Hamid; Caroline Robert; F Stephen Hodi; Jacob Schachter; Anna C Pavlick; Karl D Lewis; Lee D Cranmer; Christian U Blank; Steven J O'Day; Paolo A Ascierto; April K S Salama; Kim A Margolin; Carmen Loquai; Thomas K Eigentler; Tara C Gangadhar; Matteo S Carlino; Sanjiv S Agarwala; Stergios J Moschos; Jeffrey A Sosman; Simone M Goldinger; Ronnie Shapira-Frommer; Rene Gonzalez; John M Kirkwood; Jedd D Wolchok; Alexander Eggermont; Xiaoyun Nicole Li; Wei Zhou; Adriane M Zernhelt; Joy Lis; Scot Ebbinghaus; S Peter Kang; Adil Daud Journal: Lancet Oncol Date: 2015-06-23 Impact factor: 41.316
Authors: Mette-Triin Purde; Rebekka Niederer; Nikolaus B Wagner; Stefan Diem; Fiamma Berner; Omar Hasan Ali; Dorothea Hillmann; Irina Bergamin; Markus Joerger; Martin Risch; Christoph Niederhauser; Tobias L Lenz; Martin Früh; Lorenz Risch; David Semela; Lukas Flatz Journal: J Cancer Res Clin Oncol Date: 2021-12-07 Impact factor: 4.553